7月20日，Elevance Health盘中上涨3.08%，报385.11美元/股，成交额7387.09万美元。公司延续财报公布后的超跌修复走势。
消息面上，Q2财报发布后多家投行密集上调目标价：Guggenheim上调至455美元、Truist上调至475美元、Leerink上调至395美元。Truist在最新研报中将公司2026年EPS预期上调至27.12美元，2027年预期上调至29.14美元，认为强劲的Q2业绩和更高指引为长期改善奠定基础。公司Q2调整后EPS为7.45美元，大幅超出市场预期的6.21美元，全年指引上调至至少27美元。此前因营业利润率收窄及医疗补助业务隐忧，股价在财报后一度下挫逾10%，当前分析师平均目标价445.57美元较现价仍有显著上行空间。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.